Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer

Journal Article · Thu Jan 21 23:00:00 EST 2016 · PLoS ONE

DOI: https://doi.org/10.1371/journal.pone.0146256 · OSTI ID:1259484

Wang, Sisi ^[1]; Zhang, Hongyong ^[1]; Scharadin, Tiffany M. ^[1]; Zimmermann, Maike ^[2]; Hu, Bin ^[3]; Pan, Amy Wang ^[1]; Vinall, Ruth ^[1]; Lin, Tzu-yin ^[1]; Cimino, George ^[4]; Chain, Patrick ^[3]; Vuyisich, Momchilo ^[3]; Gleasner, Cheryl ^[3]; Mcmurry, Kim ^[3]; Malfatti, Michael ^[5]; Turteltaub, Kenneth ^[5]; de Vere White, Ralph ^[1]; Pan, Chong-xian ^[6]; Henderson, Paul T. ^[2]; Ahmad, Aamir ^[7]

---

1. Univ. of California, Davis, CA (United States)
2. Univ. of California, Davis, CA (United States); Accelerated Medical Diagnostics Inc., Dublin, CA (United States)
3. Los Alamos National Lab. (LANL), Los Alamos, NM (United States)
4. Accelerated Medical Diagnostics Inc., Dublin, CA (United States)
5. Lawrence Livermore National Lab. (LLNL), Livermore, CA (United States)
6. Univ. of California, Davis, CA (United States); VA Northern California Health Care System, Mather, CA (United States)
7. Wayne State Univ., Detroit, MI (United States)

Here, we report the development, functional and molecular characterization of an isogenic, paired bladder cancer cell culture model system for studying platinum drug resistance. The 5637 human bladder cancer cell line was cultured over ten months with stepwise increases in oxaliplatin concentration to generate a drug resistant 5637R sub cell line. The MTT assay was used to measure the cytotoxicity of several bladder cancer drugs. Liquid scintillation counting allowed quantification of cellular drug uptake and efflux of radiolabeled oxaliplatin and carboplatin. The impact of intracellular drug inactivation was assessed by chemical modulation of glutathione levels. Oxaliplatin- and carboplatin-DNA adduct formation and repair was measured using accelerator mass spectrometry. Resistance factors including apoptosis, growth factor signaling and others were assessed with RNAseq of both cell lines and included confirmation of selected transcripts by RT-PCR. Oxaliplatin, carboplatin, cisplatin and gemcitabine were significantly less cytotoxic to 5637R cells compared to the 5637 cells. In contrast, doxorubicin, methotrexate and vinblastine had no cell line dependent difference in cytotoxicity. Upon exposure to therapeutically relevant doses of oxaliplatin, 5637R cells had lower drug-DNA adduct levels than 5637 cells. This difference was partially accounted for by pre-DNA damage mechanisms such as drug uptake and intracellular inactivation by glutathione, as well as faster oxaliplatin-DNA adduct repair. In contrast, both cell lines had no significant differences in carboplatin cell uptake, efflux and drug-DNA adduct formation and repair, suggesting distinct resistance mechanisms for these two closely related drugs. The functional studies were augmented by RNAseq analysis, which demonstrated a significant change in expression of 83 transcripts, including 50 known genes and 22 novel transcripts. Most of the transcripts were not previously associated with bladder cancer chemoresistance. This model system and the associated phenotypic and genotypic data has the potential to identify some novel details of resistance mechanisms of clinical importance to bladder cancer.

• Research Organization: Lawrence Livermore National Laboratory (LLNL), Livermore, CA (United States)
• Sponsoring Organization: USDOE
• Grant/Contract Number: AC52-07NA27344
• OSTI ID: 1259484
• Journal Information: PLoS ONE, Journal Name: PLoS ONE Journal Issue: 1 Vol. 11; ISSN 1932-6203
• Publisher: Public Library of ScienceCopyright Statement
• Country of Publication: United States
• Language: English